Drug Profile
Research programme: macrocyclic peptide therapeutics - AstraZeneca/PeptiDream
Alternative Names: Oncology target antagonist - AstraZeneca/PeptiDreamLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator AstraZeneca; PeptiDream
- Class Macrocyclic compounds; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in Japan
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in United Kingdom
- 01 Nov 2012 Early research in Cancer in Japan (unspecified route)